Quantcast

Latest Daniel Von Hoff Stories

2014-06-04 20:22:06

The Pancreatic Cancer Action Network, Rising Tide Foundation for Clinical Research, and Gateway for Cancer Research Award More Than $1.2 Million in Grants MANHATTAN BEACH, Calif., June 4, 2014 /PRNewswire/ -- The Pancreatic Cancer Action Network, Rising Tide Foundation for Clinical Cancer Research (RTF-CCR) and Gateway for Cancer Research have joined forces to fight one of the deadliest and hardest-to-treat cancers. The strategic collaboration has provided $1 million to facilitate...

2014-05-29 08:28:58

Appointees join Caris' distinguished clinical and scientific team to accelerate the development and commercialization of innovative precision medicine technologies IRVING, Texas, May 29, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today that it has assembled leading scientists and clinical experts to join its newly created Scientific Advisory Board (SAB). This team will assist the...

2014-05-28 23:19:13

Tozaride Targeted Therapy Shows Tumor Reduction in Animal Model Somerville, Massachusetts (PRWEB) May 28, 2014 Andarix Pharmaceuticals, a clinical stage company, announces that its Tozaride targeted pancreatic cancer therapy has been selected for abstract publication at the 2014 ASCO meeting in Chicago, IL, May 30-June 4. The abstract - e15224: Effect of rhenium Re188-P2045 (Tozaride) on tumor growth in the AR42J rat pancreatic tumor xenograft nude mouse model - is available online at...

2014-05-21 11:53:41

Mayo Clinic Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient. They say the study, published in Molecular Cancer Research, provides key insights into the most aggressive form of the disease, which is one of the deadliest human cancers. It also offers a number of possible future clinical advances, such as a way to gauge outcome in individual patients, and insight into potential therapy to shut down...

2014-04-28 08:31:47

HACKENSACK, N.J., April 28, 2014 /PRNewswire/ -- Results from a study published in Clinical Cancer Research demonstrate that oncologists were able to accurately predict which therapies patients would respond to by using a combination of next-generation sequencing and drug sensitivity testing in mouse avatars (Champions TumorGrafts®) developed by Champions Oncology (OTC: CSBR). The paper, titled "Integrated Next Generation Sequencing and Avatar Mouse Models for Personalized Cancer...

2014-04-24 08:34:02

Will oversee Virginia G. Piper Cancer Center's internationally recognized Phase I clinical trials program SCOTTSDALE, Ariz., April 24, 2014 /PRNewswire-USNewswire/ -- Michael S. Gordon, MD, one of the greater Phoenix area's leading medical oncologists and cancer researchers, has been named the new Medical Director for the Virginia G. Piper Cancer Center Clinical Trials program at Scottsdale Healthcare. Dr. Gordon will oversee the center's internationally recognized Phase I clinical...

2014-04-08 00:21:50

Fox Family Cancer Research Funding Trust Is Contributing to Support Team SAN DIEGO, April 7, 2014 /PRNewswire-USNewswire/ -- Stand Up To Cancer (SU2C), The Lustgarten Foundation, and the Fox Family Cancer Research Funding Trust, along with the American Association for Cancer Research (AACR), SU2C's Scientific Partner, announced the formation of a Dream Team dedicated to pancreatic cancer research during a press event today at the AACR Annual Meeting 2014, held here April 5-9. Elizabeth M....

2014-04-04 23:33:41

MPI’s Drug Response Predictor (DRP) can generate new and unique clinically relevant gene signatures - a strong complementary drug development tool; TD2 is an oncology drug development company that customizes clinical trial design and execution for its customers by applying rigorous and high-throughput translational preclinical development, with best in class regulatory and clinical expertise. Scottsdale, Ariz., USA and Hoersholm, Denmark (PRWEB) April 03, 2014 Medical Prognosis...

2014-02-05 08:30:51

BUFFALO, N.Y., Feb. 5, 2014 /PRNewswire/ -- Kinex Pharmaceuticals, (Kinex), a leading specialty biotech focused on the development and commercialization of next generation oral therapies for cancer diseases has appointed Dr. Rudolf Kwan, as Chief Medical Officer and Dr. Wing-Kai Chan as Head of Clinical Operations- Asia/Pacific. Kinex currently has four oral oncology drug candidates allowed in the clinic and the appointments of Dr. Kwan and Dr. Chan adds significant expertise in...

2014-01-07 08:32:15

EAST SETAUKET, N.Y., Jan. 7, 2014 /PRNewswire/ -- John S. Kovach, M.D., President and CEO, Lixte Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of Daniel D. Von Hoff, MD, FACP, to the company's Scientific Advisory Board. "We are extremely pleased that Dr. Von Hoff has joined the Lixte Scientific Advisory Board. Dr. Von Hoff is internationally recognized as a leader in the pre-clinical and clinical development of new anti-cancer drugs. He and his colleagues were...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related